DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver ...
– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors – TriSalus is ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果